Saram ConsultingGxP & AI Consulting for Life Sciences. Custom AI integrations, Part 11 compliance validation, and equity-based engineering partnerships for biotech.Explore Services at saram.io →
← Back to Home

Bavarian Nordic

CPH: BAVA ↗$28.09 USD~$2B MCAP
#Infectious Disease#Vaccines#Public Health

Danish vaccine company developing and manufacturing prophylactic vaccines, including smallpox/mpox (JYNNEOS/IMVAMUNE) and rabies (Rabipur/RabAvert) products.

Company Info

Sector:Vaccines
Headquarters:Hellerup, Denmark
Founded:1994
Website:www.bavarian-nordic.com/

Upcoming Milestones & Key Dates

2026-Q4
Corporate Milestone

CEO transition to Tarja Stenvall

Clinical Development Pipeline

JYNNEOS / IMVAMUNE

Target: Non-replicating modified vaccinia Ankara virus
Smallpox and mpox
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Rabipur / RabAvert

Target: Inactivated rabies virus
Rabies
Preclinical
Phase 1
Phase 2
Phase 3
Approved

MVA-BN RSV

Target: MVA-BN platform
Respiratory syncytial virus
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Recent News

Leadership Team

Tarja Stenvall

President and Chief Executive Officer (incoming)

Paul Chaplin

Former President and Chief Executive Officer

Careers & Job Openings

Senior Digital Training Professional

General
Kvistgaard
Apply Now →

Operatør

General
Kvistgaard
Apply Now →

GMP Specialist

General
Kvistgaard
Apply Now →